MXPA99000372A - Products analogues of proteins cationi - Google Patents
Products analogues of proteins cationiInfo
- Publication number
- MXPA99000372A MXPA99000372A MXPA/A/1999/000372A MX9900372A MXPA99000372A MX PA99000372 A MXPA99000372 A MX PA99000372A MX 9900372 A MX9900372 A MX 9900372A MX PA99000372 A MXPA99000372 A MX PA99000372A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- amino acid
- sec
- product
- acid sequence
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 71
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 71
- 108090000715 Brain-Derived Neurotrophic Factor Proteins 0.000 claims abstract description 35
- 102000004219 Brain-Derived Neurotrophic Factor Human genes 0.000 claims abstract description 35
- 238000010521 absorption reaction Methods 0.000 claims abstract description 15
- 125000002091 cationic group Chemical group 0.000 claims abstract description 15
- 230000001965 increased Effects 0.000 claims abstract description 11
- 229920001184 polypeptide Polymers 0.000 claims description 94
- 210000004027 cells Anatomy 0.000 claims description 86
- 229940077737 Brain-Derived Neurotrophic Factor Drugs 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 17
- 108090001123 antibodies Proteins 0.000 claims description 16
- 102000004965 antibodies Human genes 0.000 claims description 16
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 102000003972 Fibroblast Growth Factor 7 Human genes 0.000 claims description 8
- 108090000385 Fibroblast Growth Factor 7 Proteins 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 102100015697 NTF3 Human genes 0.000 claims description 6
- 101700009327 NTF3 Proteins 0.000 claims description 6
- 230000001580 bacterial Effects 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 238000002741 site-directed mutagenesis Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 3
- 230000001105 regulatory Effects 0.000 claims description 3
- 210000002540 Macrophages Anatomy 0.000 claims description 2
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 claims description 2
- 206010034606 Peripheral neuropathy Diseases 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 238000007385 chemical modification Methods 0.000 claims 2
- 102000036902 Thrombopoietin Human genes 0.000 claims 1
- 108010041111 Thrombopoietin Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 230000000508 neurotrotrophic Effects 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 abstract description 15
- 102000004230 Neurotrophin-3 Human genes 0.000 description 96
- 108090000742 Neurotrophin-3 Proteins 0.000 description 96
- 229940032018 Neurotrophin 3 Drugs 0.000 description 93
- 239000000047 product Substances 0.000 description 67
- 235000018102 proteins Nutrition 0.000 description 63
- 102200029384 CLDN17 R61A Human genes 0.000 description 33
- 102220372772 PAAF1 K64D Human genes 0.000 description 32
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 19
- 238000004166 bioassay Methods 0.000 description 18
- 210000002966 Serum Anatomy 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- 238000001990 intravenous administration Methods 0.000 description 13
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 13
- 230000000275 pharmacokinetic Effects 0.000 description 12
- 239000002609 media Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000011068 load Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- ZOKVLMBYDSIDKG-CSMHCCOUSA-N Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ZOKVLMBYDSIDKG-CSMHCCOUSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- UJTZHGHXJKIAOS-WHFBIAKZSA-N Ser-Gln Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O UJTZHGHXJKIAOS-WHFBIAKZSA-N 0.000 description 8
- WPSXZFTVLIAPCN-UHFFFAOYSA-N Valyl-Cysteine Chemical compound CC(C)C(N)C(=O)NC(CS)C(O)=O WPSXZFTVLIAPCN-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 230000036912 Bioavailability Effects 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 241000237955 Nassarius Species 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000035514 bioavailability Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 108010045030 monoclonal antibodies Proteins 0.000 description 6
- 102000005614 monoclonal antibodies Human genes 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- ILDSIMPXNFWKLH-KATARQTJSA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 5
- XUUXCWCKKCZEAW-YFKPBYRVSA-N 2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 description 5
- TUTIHHSZKFBMHM-UHFFFAOYSA-N 4-amino-5-[(3-amino-1-carboxy-3-oxopropyl)amino]-5-oxopentanoic acid Chemical compound OC(=O)CCC(N)C(=O)NC(CC(N)=O)C(O)=O TUTIHHSZKFBMHM-UHFFFAOYSA-N 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 5
- QJMCHPGWFZZRID-UHFFFAOYSA-N Asparaginyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CC(N)=O QJMCHPGWFZZRID-UHFFFAOYSA-N 0.000 description 5
- NTQDELBZOMWXRS-UHFFFAOYSA-N Aspartyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CC(O)=O NTQDELBZOMWXRS-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- FUESBOMYALLFNI-VKHMYHEASA-N Gly-Asn Chemical compound NCC(=O)N[C@H](C(O)=O)CC(N)=O FUESBOMYALLFNI-VKHMYHEASA-N 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- CZVQSYNVUHAILZ-UWVGGRQHSA-N His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 CZVQSYNVUHAILZ-UWVGGRQHSA-N 0.000 description 5
- VYZAGTDAHUIRQA-WHFBIAKZSA-N L-alanyl-L-glutamic acid Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O VYZAGTDAHUIRQA-WHFBIAKZSA-N 0.000 description 5
- 241000880493 Leptailurus serval Species 0.000 description 5
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 5
- IGRMTQMIDNDFAA-UHFFFAOYSA-N Lysyl-Histidine Chemical compound NCCCCC(N)C(=O)NC(C(O)=O)CC1=CN=CN1 IGRMTQMIDNDFAA-UHFFFAOYSA-N 0.000 description 5
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 5
- YZMPDHTZJJCGEI-BQBZGAKWSA-N Ser-His Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 YZMPDHTZJJCGEI-BQBZGAKWSA-N 0.000 description 5
- WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 description 5
- FFOKMZOAVHEWET-UHFFFAOYSA-N Serinyl-Cysteine Chemical compound OCC(N)C(=O)NC(CS)C(O)=O FFOKMZOAVHEWET-UHFFFAOYSA-N 0.000 description 5
- 230000037165 Serum Concentration Effects 0.000 description 5
- GRQCSEWEPIHLBI-UHFFFAOYSA-N Tryptophyl-Asparagine Chemical compound C1=CC=C2C(CC(N)C(=O)NC(CC(N)=O)C(O)=O)=CNC2=C1 GRQCSEWEPIHLBI-UHFFFAOYSA-N 0.000 description 5
- GVRKWABULJAONN-UHFFFAOYSA-N Valyl-Threonine Chemical compound CC(C)C(N)C(=O)NC(C(C)O)C(O)=O GVRKWABULJAONN-UHFFFAOYSA-N 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 108010062796 arginyllysine Proteins 0.000 description 5
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 5
- 108010092854 aspartyllysine Proteins 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 108010084389 glycyltryptophan Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 108010009298 lysylglutamic acid Proteins 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 108010048818 seryl-histidine Proteins 0.000 description 5
- 108010026333 seryl-proline Proteins 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 108010061238 threonyl-glycine Proteins 0.000 description 5
- 108010064892 trkC Receptor Proteins 0.000 description 5
- 229920001405 Coding region Polymers 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- WXOFKRKAHJQKLT-UHFFFAOYSA-N Cysteinyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CS WXOFKRKAHJQKLT-UHFFFAOYSA-N 0.000 description 4
- 102200020881 DDX39B K95A Human genes 0.000 description 4
- 206010012601 Diabetes mellitus Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 210000001322 Periplasm Anatomy 0.000 description 4
- 102100016214 THPO Human genes 0.000 description 4
- 101710040065 THPO Proteins 0.000 description 4
- CKHWEVXPLJBEOZ-UHFFFAOYSA-N Threoninyl-Valine Chemical compound CC(C)C(C(O)=O)NC(=O)C(N)C(C)O CKHWEVXPLJBEOZ-UHFFFAOYSA-N 0.000 description 4
- LCPVBXOHXMBLFW-JSGCOSHPSA-N Trp-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)=CNC2=C1 LCPVBXOHXMBLFW-JSGCOSHPSA-N 0.000 description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- 210000004962 mammalian cells Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000006011 modification reaction Methods 0.000 description 4
- 229960000060 monoclonal antibodies Drugs 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LQJAALCCPOTJGB-YUMQZZPRSA-N (2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 description 3
- AAKRWBIIGKPOKQ-ONGXEEELSA-N 2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 3
- JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 description 3
- OSASDIVHOSJVII-UHFFFAOYSA-N Arginyl-Cysteine Chemical compound SCC(C(O)=O)NC(=O)C(N)CCCNC(N)=N OSASDIVHOSJVII-UHFFFAOYSA-N 0.000 description 3
- OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 description 3
- 102100015648 BACE2 Human genes 0.000 description 3
- 101700051947 BACE2 Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- 210000000805 Cytoplasm Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- JSIQVRIXMINMTA-ZDLURKLDSA-N Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O JSIQVRIXMINMTA-ZDLURKLDSA-N 0.000 description 3
- MRVYVEQPNDSWLH-UHFFFAOYSA-N Glutaminyl-Valine Chemical compound CC(C)C(C(O)=O)NC(=O)C(N)CCC(N)=O MRVYVEQPNDSWLH-UHFFFAOYSA-N 0.000 description 3
- JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 description 3
- MFBYPDKTAJXHNI-VKHMYHEASA-N Gly-Cys Chemical compound [NH3+]CC(=O)N[C@@H](CS)C([O-])=O MFBYPDKTAJXHNI-VKHMYHEASA-N 0.000 description 3
- YIWFXZNIBQBFHR-LURJTMIESA-N Gly-His Chemical compound [NH3+]CC(=O)N[C@H](C([O-])=O)CC1=CN=CN1 YIWFXZNIBQBFHR-LURJTMIESA-N 0.000 description 3
- 210000003000 Inclusion Bodies Anatomy 0.000 description 3
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 3
- BQVUABVGYYSDCJ-ZFWWWQNUSA-N Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-ZFWWWQNUSA-N 0.000 description 3
- UGTZHPSKYRIGRJ-YUMQZZPRSA-N Lys-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UGTZHPSKYRIGRJ-YUMQZZPRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010052388 RGES peptide Proteins 0.000 description 3
- 239000007759 RPMI Media 1640 Substances 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- LAFKUZYWNCHOHT-WHFBIAKZSA-N Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O LAFKUZYWNCHOHT-WHFBIAKZSA-N 0.000 description 3
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 108010060035 arginylproline Proteins 0.000 description 3
- 101700065210 asp1 Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010020688 glycylhistidine Proteins 0.000 description 3
- 239000001963 growth media Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 108010012581 phenylalanylglutamate Proteins 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 108010073969 valyllysine Proteins 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 2
- DWBZEJHQQIURML-IMJSIDKUSA-N Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O DWBZEJHQQIURML-IMJSIDKUSA-N 0.000 description 2
- 229960005261 Aspartic Acid Drugs 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- RGTVXXNMOGHRAY-UHFFFAOYSA-N Cysteinyl-Arginine Chemical compound SCC(N)C(=O)NC(C(O)=O)CCCNC(N)=N RGTVXXNMOGHRAY-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 2
- UQHGAYSULGRWRG-WHFBIAKZSA-N Glu-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(O)=O UQHGAYSULGRWRG-WHFBIAKZSA-N 0.000 description 2
- YSWHPLCDIMUKFE-QWRGUYRKSA-N Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YSWHPLCDIMUKFE-QWRGUYRKSA-N 0.000 description 2
- 229960002743 Glutamine Drugs 0.000 description 2
- HHSJMSCOLJVTCX-UHFFFAOYSA-N Glutaminyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CCC(N)=O HHSJMSCOLJVTCX-UHFFFAOYSA-N 0.000 description 2
- CTCFZNBRZBNKAX-UHFFFAOYSA-N Histidinyl-Glutamine Chemical compound NC(=O)CCC(C(O)=O)NC(=O)C(N)CC1=CN=CN1 CTCFZNBRZBNKAX-UHFFFAOYSA-N 0.000 description 2
- 210000004408 Hybridomas Anatomy 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- OAPNERBWQWUPTI-YUMQZZPRSA-N Lys-Gln Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O OAPNERBWQWUPTI-YUMQZZPRSA-N 0.000 description 2
- JPNRPAJITHRXRH-UHFFFAOYSA-N Lysyl-Asparagine Chemical compound NCCCCC(N)C(=O)NC(C(O)=O)CC(N)=O JPNRPAJITHRXRH-UHFFFAOYSA-N 0.000 description 2
- PESQCPHRXOFIPX-RYUDHWBXSA-N Met-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-RYUDHWBXSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- JXWLMUIXUXLIJR-QWRGUYRKSA-N Phe-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 JXWLMUIXUXLIJR-QWRGUYRKSA-N 0.000 description 2
- FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102200032113 SNX6 R97A Human genes 0.000 description 2
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 description 2
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 2
- RZEQTVHJZCIUBT-UHFFFAOYSA-N Serinyl-Arginine Chemical compound OCC(N)C(=O)NC(C(O)=O)CCCNC(N)=N RZEQTVHJZCIUBT-UHFFFAOYSA-N 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 229960002180 Tetracycline Drugs 0.000 description 2
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- HYLXOQURIOCKIH-VQVTYTSYSA-N Thr-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N HYLXOQURIOCKIH-VQVTYTSYSA-N 0.000 description 2
- IOWJRKAVLALBQB-IWGUZYHVSA-N Thr-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O IOWJRKAVLALBQB-IWGUZYHVSA-N 0.000 description 2
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 2
- WCRFXRIWBFRZBR-GGVZMXCHSA-N Thr-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WCRFXRIWBFRZBR-GGVZMXCHSA-N 0.000 description 2
- LWFWZRANSFAJDR-JSGCOSHPSA-N Trp-Val Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O)=CNC2=C1 LWFWZRANSFAJDR-JSGCOSHPSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 230000002051 biphasic Effects 0.000 description 2
- -1 but not limited to Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 238000010192 crystallographic characterization Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- KGNSGRRALVIRGR-UHFFFAOYSA-N gln-tyr Chemical compound NC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 KGNSGRRALVIRGR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000006956 minimum essential medium Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 108091007521 restriction endonucleases Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- YAMUFBLWGFFICM-PTGWMXDISA-N 1-O-oleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C YAMUFBLWGFFICM-PTGWMXDISA-N 0.000 description 1
- MHKBMNACOMRIAW-UHFFFAOYSA-N 2,3-dinitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O MHKBMNACOMRIAW-UHFFFAOYSA-N 0.000 description 1
- JEPVUMTVFPQKQE-AAKCMJRZSA-N 2-[(1S,2S,3R,4S)-1,2,3,4,5-pentahydroxypentyl]-1,3-thiazolidine-4-carboxylic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C1NC(C(O)=O)CS1 JEPVUMTVFPQKQE-AAKCMJRZSA-N 0.000 description 1
- CFBILACNYSPRPM-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid Chemical compound OCC(N)(CO)CO.OCC(CO)(CO)NCC(O)=O CFBILACNYSPRPM-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101700061329 ARTN Proteins 0.000 description 1
- 230000035533 AUC Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 108009000433 Amyotrophic lateral sclerosis (ALS) Proteins 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- QADCERNTBWTXFV-JSGCOSHPSA-N Arg-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCNC(N)=N)N)C(O)=O)=CNC2=C1 QADCERNTBWTXFV-JSGCOSHPSA-N 0.000 description 1
- VGRHZPNRCLAHQA-UHFFFAOYSA-N Aspartyl-Asparagine Chemical compound OC(=O)CC(N)C(=O)NC(CC(N)=O)C(O)=O VGRHZPNRCLAHQA-UHFFFAOYSA-N 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 230000035639 Blood Levels Effects 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 101700066277 COS-1 Proteins 0.000 description 1
- 229940041514 Candida albicans extract Drugs 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 230000037242 Cmax Effects 0.000 description 1
- 241000595586 Coryne Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 230000036469 Elimination phase Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- VHLZDSUANXBJHW-UHFFFAOYSA-N Glutaminyl-Phenylalanine Chemical compound NC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 VHLZDSUANXBJHW-UHFFFAOYSA-N 0.000 description 1
- AJHCSUXXECOXOY-NSHDSACASA-N Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-NSHDSACASA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229960004198 Guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N Guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 210000004324 Lymphatic System Anatomy 0.000 description 1
- YSZNURNVYFUEHC-BQBZGAKWSA-N Lys-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YSZNURNVYFUEHC-BQBZGAKWSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101700037190 NAGS Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108010008267 Nerve Growth Factors Proteins 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- SSJMZMUVNKEENT-IMJSIDKUSA-N Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CO SSJMZMUVNKEENT-IMJSIDKUSA-N 0.000 description 1
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920000978 Start codon Polymers 0.000 description 1
- 239000004473 Threonine Chemical group 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010087049 alanyl-alanyl-prolyl-valine Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 108010046910 brain-derived growth factor Proteins 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000006143 cell culture media Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N ethylene glycol monomethyl ether Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000003899 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940077456 human brain-derived neurotrophic factor Drugs 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000007758 minimum essential media Substances 0.000 description 1
- 230000002297 mitogenic Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000010927 mucositis Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000010915 one-step procedure Methods 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 201000010830 physical disease Diseases 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- NBBJYMSMWIIQGU-UHFFFAOYSA-N propionic aldehyde Chemical group CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000284 resting Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 108010064880 trkB Receptor Proteins 0.000 description 1
- 102000015534 trkB Receptor Human genes 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- IOUPEELXVYPCPG-UHFFFAOYSA-N val-gly Chemical compound CC(C)C(N)C(=O)NCC(O)=O IOUPEELXVYPCPG-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Abstract
The present invention relates to the life of circulation and / or in vivo absorption of the therapeutic, cationic proteins, which include but are not limited to basic proteins such as NT-3 and BDNF, can be increased by the generation of analogous products which they have a lower isoelectric point and, preferably, also a charge of the lower protein relative to the native sequence protein.
Description
ANALOGUE PROTEIN PRODUCTS CATIQNICAS
FIELD OF THE INVENTION
This invention relates generally to therapeutically active cationic protein polypeptide analog products, including, but not limited to, neurotrophic factor analogues known as neurotrophin-3 (NT-3) and brain-derived neurotrophic factor (BDNF). . More specifically, the invention relates to positively charged polypeptides in which modifications have been made to the native sequence, such that the analogous products have lower isoelectric points and, concomitantly, longer circulation times and / or improved absorption afterwards. of parenteral administration. The invention also relates to materials and methods for the recombinant production of such polypeptide analog products, to antibodies thereof, and to pharmaceutical compositions containing the analogous products that can be used for the treatment of various diseases and disorders,
REF .: 29077 BACKGROUND OF THE INVENTION
After administration of a therapeutic protein by a parenteral means, such as by subcutaneous, intravenous or intramuscular injection, the pharmacokinetic properties such as bioavailability, circulation time and rate of elimination can vary widely from protein to protein. Although there are active efforts in many laboratories to develop alternative routes of administration for protein products, little is known about the factors that govern the pharmacokinetic behavior of protein therapeutic products after such parenteral administration. It has been known that an increase in the molecular weight of a protein can result in a preferential uptake by the lymphatic system before the blood capillaries; Supersaxo et al., Phamaceutical Res., Volume 7, page 167 et esq. (1990). The molecular size of the therapeutic protein also plays a key role in insulin uptake, where the dissociation of a zinc-induced hexamer to a monomeric form has been shown to be the speed limitation step in the absorbance of insulin; Kang et al., Diabetes Care, Volume 14, pages 942-948 (1991). The clinical analysis in diabetic patients of the monomeric insulin analogue products, in which the exome association site has been eliminated, has demonstrated a faster uptake, leading to significant improvements in glucose control in diabetic patients; see Brange et al., Nature, Volume 333, page 679 et seq. (1988).
BRIEF DESCRIPTION OF THE INVENTION
To assess the impact of the isoelectric point (pl) on the pharmacokinetic behavior of proteins, certain NT-3 and BDNF analog products have been produced, in particular, which have a relatively lower pH, yet retain the structure and biological activity of the protein in its "native" state (ie, the protein of the naturally occurring amino acid sequence, as well as the met "1" version thereof, both of which are referred to herein as "uncultivated type" ") From these studies, it has now been discovered that protein analog products designed to possess a lower pl and / or lower charge under physiological conditions than the non-cultured type molecule, can also exhibit in vivo circulation times. longer (ie, "lifespan") and improved absorption after administration by injection Although the invention is illustrated in this description with particular reference In addition to the NT-3 and human BDNF, this has broader applicability to any cationic protein, and particularly basic proteins which in their native sequence have a pl greater than about 7.0. It should be noted that the terms "protein" and
"polypeptide" are used interchangeably throughout this description to imply the same thing. Established brieflyThe present invention is analogous products substitution, insertion and deletion of therapeutic proteins, cationic, and / or chemically modified versions of such therapeutic proteins, that are characterized by a lower pl while also exhibiting in longer circulation and / or higher absorption relative to unmodified (ie, native sequence) proteins. The analogous proteins of this invention are typically human therapeutic proteins which are usually, but not necessarily, basic proteins. Preferably, these proteins also have a lower charge under physiological conditions compared to the basic protein, unmodified. The present invention also concerns materials and methods for the recombinant production of such analogues (as a preferred practical method), as well as antibodies raised against analogs protein products, and to pharmaceutical compositions containing the analogues as agents biologically active for use in the treatment of diseases and physical disorders.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGURE 1 shows the amino acid sequence for human NT-3 of the non-cultured type (ie, "native" sequence) which has been recombinantly produced in bacterial E cells. cal i and expressed with a methionine residue present at the N-terminus, ie r-metHuNT-3 (SEQ ID NO: 1). In the Figure, amino acid numbering begins with the first residue after the initial methionine (met "1), since the naturally occurring protein is normally expressed in mammalian cells without the methionine residue. of Sequences in the present account the Met residue as +1.) FIGURE 2 shows the nucleic acid sequence (SEQ ID NO: 2, and FIGURE 2A) and the amino acid sequence (SEQ ID NO: 2, and FIG. NO: 3, and Figure 2B) of a r-metHuNT-3 polypeptide analog product of the present invention, specifically, NT-3 (i-? I9) R61A, K64D (with the amino acid numbering in the starting Figure with the first residue after the initial methionine.) FIGURE 3 shows the nucleic acid sequence (SEQ ID NO: 4, and Figure 3A) and the amino acid sequence (SEQ ID NO: 5) and Figure 3B) of another r-metHuNT-3 polypeptide analogue product according to the present invention, specific n, NT-3 (? -? i7) R61A, K64D (the numbering of amino acids in the Figure starts again with the first residue after the initial methionine). FIGURE 4 shows the calibration curves of the ELISA (standard) assay for the NT-3 of the non-cultured type (ie, having the ID of SEQ.NO.:1) and for the analogous products of the NT-3. of the IDs. FROM THE SEC. NOS: 3 and 5. The optical density is marked against the concentration of the sample in nanograms per milliliter (ng / ml). The cross-reactivity for the NT-3 analog products in the ELISA assay is approximately ten percent. Serum samples from pharmacokinetic studies were analyzed by the ELISA, and concentrations of NT-3 of the non-cultured type and of the NT-3 analog products were determined by calibration against the appropriate standard curve. FIGURE 5 depicts a high performance, size exclusion liquid chromatogram (SEC-HPLC) in which the NT-3 of the non-cultured type is compared to the NT-3 analog products of Figures 2 and 3. The units of absorbance ("AU") are marked on the vertical axis, and the elution time to peak (in minutes) is shown on the horizontal axis. As shown, the analogous products are coeluted with the molecule of the non-cultured type, demonstrating that the non-covalent dimer structure of NT-3 of the non-cultured type has not been broken in any of the analogs. No aggregated protein was detected in any of these preparations. The Figure represents: () NT-3 of the non-cultivated type;
() NT-3 (1-u7) R61A, K64D; and (•) FIGURE 6 depicts a high performance liquid cation exchange chromatogram (CEX-HPLC) in which the NT-3 of the non-cultured type is compared to the NT-3 analog products of Figures 2 and 3. The "AU" (vertical axis) indicates the absorbance units. The peak elution time is shown on the horizontal axis. In this figure the analogous products are eluted earlier than the NT-3 of the non-cultured type, which is consistent with the lower isoelectric points of the analogues. The figure represents
() NT-3 of the non-cultivated type; ()
NT-3 (? - u7, R61A, K64D; and (.) NT-3 a-119) R61A, K64D. FIGURE 7 depicts a silver-stained SDS polyacrylamide gel electrophoresis chromatogram (SDS-PAGE) in which the NT-3 of the non-cultured type (see Figure 1) is compared to the NT-3 analog products of the Figures 2 and 3. All three samples were run as a single band with approximately the same molecular weight of the monomeric form. None of the samples is observed to contain significant amounts of higher molecular weight oligomers or lower molecular weight fragments. Lane 1: NT-3 (1-? 17) R61A, K64 D, 2.5 μg; Lane 2: NT-3a-u9) R61A, K64D, 2.5 μg; Track 3; NT-3 of the non-cultivated type, 2.5 μg; Lane 4: NT-3 of the non-cultivated type, 12.5 μg; Clue 5: molecular weight markers. FIGURE 8 shows the serum concentration profiles (in nanograms per milliliter) versus time (in hours?) For the ID proteins. FROM THE SEC. US: 1, 3 and 5 after intravenous (IV) administration to test rats. The dose level was 1 milligram per kilogram (mg / kg) of body weight. The concentration profiles are biphasic. The initial distribution phase was followed by a slower elimination phase. Each point on the graph represents an average of three animals. FIGURE 9 shows the serum concentration curves (in nanograms per milliliter) versus time (in hours) in rats for the ID proteins. FROM THE SEC. NOS: 1, 3 and 5 after subcutaneous administration (SC) of one mg / kg, with each point on the graph representing again an average of three animals. The absorption phase is characterized by an increase in serum concentration to a peak. NT-3 of the non-cultivated type (SEQ ID NO: 1) showed the fastest decrease after reaching the maximum concentration.
DETAILED DESCRIPTION OF THE INVENTION
The principles of this invention have a broad applicability to any cationic protein for which a reduction in the pl and, optionally the loading of the prctein will result in an increase in the therapeutically relevant biological properties such as circulation time and / or absorption after parenteral administration. By way of illustration, such proteins include, but are not limited to, basic proteins such as NT-3, BDNF, growth factor and macrophage differentiation, and various known isoforms thereof that have essentially the same ability to increase platelet production. sanguineous in vi and ex vi vo (collectively referred to herein as "MGDF"), and keratinocyte growth factor (KGF). Detailed descriptions of these factors, their biological properties and methods for their preparation and analysis are given in the patent literature: NT-3 in the published PCT application WO 91/03569; BDNF in U.S. Patent Nos. 5,180,820 No. 5,229,500, No. 5,438,121 and No. 4,453,361 and in published PCT application WO 91/03568; MGDF in published PCT applications WO 95/26745, WO 95/21919, and WO 95/21920; and KGF in the published PCT application WO 90/08771. In essence, the aim of this invention is to make one or more modifications to the primary structure of the protein of the non-cultured type which retains the protein structure and the biological activity of the protein, but which also results in a lower isoelectric point and , preferably, a lower charge at a physiological pH. The particular manner in which these modifications are made is not critical, and any procedure which makes the aforementioned changes can be used to achieve the increases described in the properties. By way of illustration only, appropriate modifications can be made through the use of site-directed mutagenesis involving the addition of acidic residues to the sequence by insertion and / or replacement mutations, and / or removal of basic residues by mutations. of suppression and / or replacement. Alternatively, the chemical groups or portions can also be added to the selected sites (ie, at the amino acid residues) in the protein chain of the non-cultured type molecule to realize the same final purpose (i.e., the reduction of the pl and the load with the conservation of the structure and the biological activity). A specific example is the succinylation of the selected residues in the protein chain. The nucleic acids which encode the analogous products of the protein according to this invention (ie, wherein one or more amino acids are designed to differ from the non-cultured type polypeptide) can be produced using site-directed mutagenesis or amplification of PCR in which the polymer (s) have the mutations of the desired points. For a detailed description of suitable mutagenesis techniques, see Sambrook, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989) and / or Ausubel et al., Editors, Current Protocols in Molecular Biology, Green Publishers Inc. and Wiley and Sons, NY (1994). Chemical synthesis can also be used using the methods described by Engels et al., In Angew. Chem. Intl. Ed., Volume 28, pages 716-734 (1989), for preparing such nucleic acids. The DNA molecules can be used to express the polypeptides analogous products of the invention by recombinant methods familiar to those skilled in the art, including but not limited to the methods described in the patents or patent applications mentioned above for NT-3 , BDNF, KGF and MGDF. By way of illustration, a nucleic acid sequence encoding an analogous product polypeptide of this invention is inserted into a biologically functional vector, appropriate (eg, circular plasmid or viral DNA) for expression in a suitable host cell the vector includes regulatory sequences for the expression of the nucleic acid sequence, inserted and selected to be functional in the particular host cells, employed ( that is, the vector is compatible with the machinery of the host cell, such that amplification and / or expression of the gene can occur). The polypeptide can be amplified / expressed in prokaryotic host cells, yeast, insects (baculovirus systems) and / or eukaryotic cells. The selection of the host cell will depend at least in part on whether the polypeptide expression product should be glycosylated. If glycosylation is desired, then yeast, insect or mammalian host cells are preferred for use. Typically, the vectors will contain a 5 'flanking sequence (also referred to as a "promoter") and other regulatory elements, as well as enhancer (s), an element of origin or application, a transcriptional termination element, an intron sequence, complete containing a donor and acceptor binding site, a signal peptide sequence, a ribosome binding site element, a polyadenylation sequence, a polylinker region for inserting the nucleic acid encoding the polypeptide to be expressed, and a selectable marker element. The 5 'flanking sequence may be the innate 5' flanking sequence of the gene of the non-cultivated type, or it may be homologous (ie, of the same species and / or strain as the host cell), heterologous (i.e., of a species). different from the species of the host cell or strain), hybrid (i.e., a combination of 5 'flanking sequences from more than one source), or synthetic. The source of the 5 'flanking sequence can be any unicellular prokaryotic or eukaryotic organism, any vertebrate or invertebrate organism, or any plant, with the proviso that the 5' flanking sequence is -functional in, and can be activated by, the the host cell. The origin of the replication element is typically a part of the commercially acquired prokaryotic expression vectors, and aids in the amplification of the vector in a host cell. Amplification of the vector to a certain number of copies may, in some cases, be important for optimal expression of the polypeptide. If the selection vector does not contain an origin of the replication site, one can be chemically synthesized based on a known sequence and then ligated into the vector. The transcription termination element is typically located 3 'to the end of the polypeptide coding sequence and serves to terminate transcription to the polypeptide. Usually, the transcription termination element in prokaryotic cells is a fragment rich in G-C followed by a poly-T sequence. While the element is easily cloned from a library or even commercially purchased as part of a vector, it can also be easily synthesized using methods for the synthesis of nucleic acids such as those referred to above. A selectable marker gene element encodes a protein necessary for the survival and growth of a host cell grown in a selective culture medium. Selection marker genes, typical encode proteins that (a) confer resistance to antibiotics or other toxins, for example ampicillin, tetracycline or kanamycin for prokaryotic host cells, (b) complement auxotrophic deficiencies of the cell complement; or (c) provide clinical nutrients not available from complex media. Preferred selectable markers are the kanamycin resistant gene, the ampicillin resistant gene, and the tetracycline resistant gene. The ribosome binding element, commonly called the Shine-Dalgarno sequence (for prokaryotic organisms) or the Kozak sequence (for eukaryotic organisms), is necessary for the initiation of translation for mRNA. The element is typically located 3 'to the promoter and 5' to the coding sequence of the polypeptide to be synthesized. The Shine-Dalgarno sequence is varied but is typically a polypurine (ie, having a high content of A-G). Many Shine-Dalgarno sequences have been identified, each of which can be easily synthesized using the methods set forth above and can be used in a prokaryotic vector. In those cases where it is desirable that the polypeptide be secreted from the host cell, a signal sequence can be used to direct the polypeptide out of the host cell where it is synthesized. Typically, the signal sequence is located in the coding region of the nucleic acid sequence, or directly at the 5 'end of the coding region. Many signal sequences have been identified, and any one of them that is functional in the selected host cell can be used herein. Consequently, the signal sequence can be homologous or heterologous to the polypeptide. Additionally, the signal sequence can be synthesized chemically using methods such as those referred to above. The host cells can be prokaryotic host cells (such as E. coli) or eukaryotic host cells (such as yeast, insect or vertebrate cells). The host cells, when cultured under suitable nutrient conditions, can synthesize the peptide, which can be subsequently collected by isolating the culture medium (if the host cell secretes it in the medium) or directly from the host cells that host it. produces (if not secret). After the collection the polypeptide can be purified using methods such as molecular tint chromatography, affinity chromatography and the like. In general, if the polypeptide is expressed in E. col i, this will contain a methionine residue at the N-terminus in its recovered form (ie, met "1), unless it is expressed in an E. coli strain in which the methionine is enzymatically split by the host .
Suitable cells or cell lines can also be mammalian cells, such as Chinese hamster ovary (CHO) cells or 3T3 cells. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, selection and production and purification of the product are well known in the art. Other suitable mammalian lines are the COS-1 and COS-7 monkey cell lines, and the CV-1 cell line. Additional, exemplary mammalian host cells include primate cell lines and rodent cell lines, including transformed cell lines. Also suitable are normal diploid cells, cell strains derived from the culture of primary tissue, as well as primary explantations. The candidate cells may be genotypically deficient in the selection gene, or they may contain a selection gene that acts dominantly. Still other suitable mammalian cell lines include, but are not limited to, HeLa, mouse L-929 cells, 3T3 lines derived from Swiss, cell lines from Balb-c or NIH mice, BHK hamster or Hak. The insertion (also referred to as "transformation" or "transfection") of the vector in the selected host cell can be performed using calcium chloride, electroporation, microinjection, lipofection or the DEAE-dextran method. The selected method will be in part a function of the type of host cell to be used. These methods and other suitable methods are well known to the skilled artisan, and are discussed, for example, in Sambrook et al., Supra. The host cells containing the vector can be cultured using normal means well known to the skilled artisan. The media will usually contain all the nutrients necessary for the growth and survival of the cells. The suitable means for the culture of the E cells. col i are, for example, Caldo Luria (LB) and / or Caito Terrific (TB). Suitable media for the culture of eukaryotic cells are RPMI 1640, MEM, DMEM, all of which can be supplemented with serum and / or growth factors as required by the particular cell line being cultured. A suitable medium for insect culture is Grace medium supplemented with levadurolate, lactalbumin hydrolyzate, and / or fetal bovine serum as necessary. Typically, an antibiotic or other compound useful for the selective cultivation of transformed cells is added as an adjunct to the medium.
The compound to be used will be dictated by the appropriate marker element present in the plasmid with which the host cell is transformed. For example, where the selectable marker element is resistant to kanamycin, the compound added to the culture medium will be kanamycin. The amount of the polypeptide produced in the host cell can be assessed using standard methods known in the art. Such methods include, without limitation, Western blot analysis, SDS-polyacrylamide gel electrophoresis, non-denaturing gel electrophoresis, HPLC separation, immunoprecipitation, and / or activity assays such as gel exchange assays. DNA binding. If the polypeptide has been designed to be secreted from the host cells, most of the polypeptide will probably be found in the cell culture medium. However, if the polypeptide is not secreted, it will be present in the cytoplasm (for eucaryotic, bacterial, Gram-positive and insect host cells) or in the periplasm (for host cells of Gram-negative bacteria.) For the intracellular polypeptide , typically the host cells are first disrupted mechanically or osmotically to release the cytoplasmic contents in a buffered solution.The polypeptide is then isolated from this solution.The purification of the polypeptide from the solution can be carried out subsequently using a variety of techniques. has been synthesized such that it contains a residue such as Hexahistidine or another small peptide in either its carboxyl or amino terminus, it can be modified in a one-step procedure by passing the solution through an affinity column where the column matrix has a high affinity for the residue or for the polypeptide directly (ie, a monoclonal antibody). For example, polyhistidine binds with great affinity and specificity to nickel, so a nickel affinity column (such as Qiagen nickel columns) can be used for purification. (See, for example, Ausubel et al., Eds., Current Protocols in Molecular Biology, John Wiley & amp;; Sons, New York, 1994). Where, on the other hand, the polypeptide has no residues or antibodies are available, other well-known purification methods can be used. Such methods include, without limitation, ion exchange chromatography, molecular sieve chromatography, HPLC, negative gel electrophoresis in combination with gel elution and preparative isoelectric focusing (machine / "Isoprime" technique, Hoefer Scientific). In some cases, two or more of these techniques can be combined to achieve increased purity. If it is anticipated that the polypeptide will be found primarily in the periplasmic space of the bacterium or the cytoplasm of eukaryotic cells, the contents of the periplasm or cytoplasm, including the inclusion bodies (eg, Gram-negative bacteria) if the polypeptide has formed such complexes can be extracted from the host cell using any normal technique known to the skilled artisan. For example, the host cells can be lysed to release the contents of the periplasm by the use of a French press, homogenization, and / or treatment with high frequency sound waves. The homogenized product can then be centrifuged. In addition to the preparation of the polypeptide analog products of this invention by recombinant DNA techniques, the polypeptides can be prepared by chemical synthesis methods (such as solid phase peptide synthesis) using techniques known in the art, including that exposed. by Merrifield et al. in J. Am. Chem. Soc., Volume 85, page 2149 (1964), by Houghten et al., in Proc. Nati Acad. Scie, USA, Volume 82, page 5132 (1985) and by Stewart and Young in Solid Phase Peptids Synthesis, Pierce Chem. Co. Rockford, IL (1984). Chemically synthesized polypeptides can be oxidized using the methods set forth in those references to form disulfide bridges. The pl and loading of the protein analog products resulting from any of the aforementioned methods can be measured using standard techniques, such as those described further below in conjunction with the specific embodiments. Chemically modified polypeptide compositions (ie, "derivatives") wherein the polypeptide is linked to a polymer in order to modify the properties are included within the scope of the present invention. The polymer is typically soluble in water, so that the protein to which it binds does not precipitate in an aqueous environment, such as a physiological environment. The polymer can have an individual reactive group, such as an active ester for acylation or an aldehyde for alkylation, so that the degree of polymerization can be controlled. A preferred reactive aldehyde is propionaldehyde of polyethylene glycol, which is stable in water, or monoalkoxy or aryloxy derivatives of 1 to 10 carbon atoms thereof (see U.S. Patent No. 5,252,714). The polymer can be branched or unbranched. Preferably, for the therapeutic use of the preparation of the final product, the polymer will be pharmaceutically acceptable. The water soluble polymer, or mixture thereof if desired, can be selected from the group consisting of, for example, polyethylene glycol (PEG), monomethoxy polyethylene glycol, dextran, cellulose or other polymers based on carbohydrates, polyethylene glycol poly ( N-vinylpyrrolidone), propylene glycol homopolymers, a copolymer of polypropylene oxide / ethylene oxide, polyoxyethylated polyols (for example, glycerol) and polyvinyl alcohol. In general, the polypeptide analog products of this invention will be useful for the same purposes for which proteins of the non-cultured type from which they are derived are known to be useful. For example, NT-3 is currently under clinical study for the treatment of peripheral neuropathies (including diabetics), while BDNF is under clinical study for the treatment of amyotrophic lateral sclerosis (ALS). KGF is known to be active as a tissue growth and repair factor, and is currently in clinical development for the treatment of mucositis induced by chemotherapy or radiation. MGDF (in the form of a derivative treated with PEG) is in clinical development for the stimulation of platelet production as an adjunct to thrombositopenia induced by chemotherapy. However, it is expected that the analogous products of this invention offer advantages over the unmodified forms from the standpoint of increased therapeutic lifetime and absorbability. For therapeutic purposes, the analogous product polypeptides of this invention will typically be formulated in suitable pharmaceutical compositions adapted for therapeutic delivery, which constitutes a further aspect of this invention. Such pharmaceutical compositions will typically comprise a therapeutically active amount of an analogous polypeptide, alone or together with one or more excipients, carriers or other ingredients normal to a pharmaceutical composition. The carrier material can be water for injection, preferably supplemented with other common materials in the solutions for administration to mammals. Typically, the analogous product polypeptide will be administered in the form of a composition comprising a purified form of the polypeptide (which may be chemically modified) in conjunction with one or more physiologically acceptable carriers, excipients or diluents. The buffered, neutral saline solution or the saline solution mixed with serum albumin are exemplaryly suitable carriers. Other carriers, diluents and excipients can be included as desired. The pharmaceutical compositions of this invention can be prepared for storage by mixing the selected composition having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences, 18th edition, AR Gennaro, ed., Mack Publishing Company, 1990) in the form of a lyophilized cake or an aqueous solution. Acceptable carriers, excipients or stabilizers are non-toxic to the receptors and are preferably inert in the doses and concentrations employed, and include buffers such as phosphate, citrate, acetate, succinate or other salts of organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, aspargin, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt formation counterions such as sodium; and / or nonionic surfactants such as Tween, Pluronics or polyethylene glycol (PEG). Any composition of this invention that is proposed to be used for in vi ve administration must be sterile. Sterilization is easily carried out by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using these methods can be conducted either before, or after, lyophilization and reconstitution. The composition for parenteral administration will ordinarily be stored in the lyophilized form or in solution. The amount of polypeptide that will be effective in the treatment of a particular disorder or condition will depend on the nature of the polypeptide and the disorder or condition, as well as the age and general health of the patient, and can be determined by clinical, normal procedures. Where possible, it will be desirable to determine the dose response curve of the first in vivo pharmaceutical composition, such as in bioassay systems, and then in animal model systems, useful in vivo prior to human analysis. In general, suitable in vivo amounts can be developed based on an understanding of the therapeutically effective doses known for the protein of the non-cultured type on which the analogues are based. The expert practitioner, considering the therapeutic context, type of disorder under treatment, etc., will be able to find out the proper dosage without undue effort. Introduction methods for administration purposes include intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous. In addition, the invention also encompasses pharmaceutical compositions comprising the polypeptide analog products administered by means of liposomes, microparticles or microcapsules, which may be particularly useful for achieving sustained release. Various delivery devices may be necessary in the case of some of the polypeptide analog products, such as those of NT-3, BDNF and other neurotrophic factors proposed for the treatment of neurological conditions associated with the brain and other areas of the nervous system. central. Such devices may include osmotic implants and pumps for intrathecal and intracranial delivery, for example. The analogous products of this invention can also be used according to normal procedures to generate antibodies that are useful for medically related purposes, such as for monitoring the blood levels of the corresponding analogue product in a subject undergoing therapeutic treatment. . Various methods known in the art can be employed for the production of polyclonal antibodies that recognize epitopes of the polypeptides. For the production of antibodies, several host animals can be immunized by injection with an analogous polypeptide, or fragment or derivative thereof, including but not limited to rabbits, mice, rats, etc. Various adjuvants can be used to increase the immune response, depending on the host species, including but not limited to, Freund mineral gels such as aluminum hydroxide (alum), surfactants such as lysolecithin, pluronic polyols, polyanions, polypeptides, oil emulsions, keyhole limpet emocianins, dinitrophenol, and potentially useful human adjuvants such as Bacille Calmette-Guerin and Coryne acteriujp pa rvum. For the preparation of the monoclonal antibodies directed towards the analogous polypeptides, any technique which provides for the production of antibody molecules by the continuous cell lines in culture can be used. For example, the hybridoma technique originally developed by Kohler and Milstein and described in Nature, Volume 256, pages 495-497 (1975), as well as the trioma technique, the human B-cell hybridoma technique described by Kozbor and collaborators in Immunology Today, volume 4, page 72 (1983) and the EBV-hybridoma technique for producing monoclonal antibodies described by Colé et al., in "Monoclonal Antibodies and Cancer Therapy", Alan R. Liss, Inc., pages 77- 96 (1985), all are useful for the preparation of monoclonal antibodies. In addition, a molecular clone of an antibody can be prepared for an epitope or epitopes of the polypeptide with known techniques. In particular, the recombinant DNA methodology can be used to construct nucleic acid sequences encoding a moclonal antibody molecule or an antigen binding region thereof.; see, for example, Maniatis et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1982). The antibodies are useful for diagnostic purposes both in vivo and in vitro, particularly in forms labeled to detect the presence of the polypeptides in a sample of fluid or tissue.
DESCRIPTION OF THE PREFERRED MODALITIES
The invention is described in further detail with reference to the following materials, methods, procedures and test results. The amino acid residues of the proteins are identified in the conventional manner using the three letter designations, established (for example, "met" for methionine, "val" for valine, etc.) or in some cases the individual letter designations, established (for example, "M" for methionine, "R" for arginine, etc.) throughout the text.
Materials and methods:
Preparation of NT-3 analog products. The amino acid residues for substitution in the native sequence of human NT-3 were selected with the aid of conservation of the core structure and biological / therapeutic activity (see Holland et al., J. Mol. Biol. Volume 239, pages 385-400, 1994, Ibanez et al., In Cell, Volume 69, pages 329-341, 1992 and also in EMBO Journal, Volume 12, pages 2281-2293, 1993). The actual substitutions that were made in the native sequence of human NT-3 are reflected in the sequences shown in Figures 2 and 3, respectively. In an analogue, shown in Figure 2, the following two substitutions were made: the arginine at position 61 (arg6?) Was replaced by alanine (ala), and the lysine at position 64 (lys? I) was replaced with aspartic acid (asp) This analogous products was designated "NT-3 (? - ?? 9) R61A, K64D". A second analogue, shown in Figure 3, had those same two amino acid substitutions and, in addition, truncated at residue 117 (thereby suppressing argua and thrug). this analogous product was designated "NT-3 (? - u7) R61A, K64D". To create these analogues, the mutations were introduced into the human NT-3 sequence by means of the Polymerase Chain Reaction Technology, Standard (PCR). For NT-3 (1-u9) R61A, K64D, oligonucleotides chemically synthesized in pairs were used to create fragments of the NT-3 gene comprising the frontal portion to the site of the codon mutations corresponding to the portions of the gene. and 64 and the posterior portion of the mutant codon gene at the end. A second PCT was carried out by combining the front and back portions to create the full-length nucleic acid molecule encoding the two mutations at positions 61 and 64, respectively. For NT-3 (? -117) R61A, K64D, the above procedure was repeated, except that the posterior portion omitted the codons for arginine and threonine at positions 118 and 119.
Expression in E col i. An encoding of the DNA sequence for a methionine residue at the 5 'end was included to express the analogous products in E. coli and a stop codon was placed at the 3' end in each case. In addition, the cut sites for the Xbal and HindIII restriction enzymes were placed at the 5 'and 3' ends of the gene, respectively, and a synthetic ribosome binding site was placed in an appropriate substance upstream of the initiating methionine. . The resulting synthetic gene fragments, flanked by the Xbal and HindIII restriction sites at the 5 'and 3' ends, respectively, contained a ribosome binding site, the ATG start codon (encoding methionine), the sequence of analog coding, and a stop codon. The fragments were digested with the restriction endonucleases Ndel and BamHI and then ligated into the vector pAMG12. The expression plasmid pAMG12 can be derived from the plasmid pCFM1656 (acquisition record of ATCC No. 69576, deposited on February 24, 1994) by making a series of base changes directed to the site by PCR overlaying the oligomutagenesis and the substitutions of DNA sequences. Starting with the Bglll site (base pair of plasmid No. 180) immediately 5 'to the replication promoter of the PcopB plasmid and proceeding to the plasmid replication genes, the changes of the base pairs (bp) are as follows:
bp DAMG12 no. bp in PCFM1656 bp changed to. in PAMG12 # 204 T / AC / G # 428 A / TG / C # 509 G / AC / T # 617 insert two bp G / C # 679 G / CT / A # 980 T / AC / G # 994 G / CA / T # 1004 A / TC / G # 1007 C / GT / A # 1028 A / TT / A # 1047 C / GT / A # 1178 G / CT / A # 1466 G / CT / A # 2028 G / C deletion of bp # 2187 C / GT / A # 2480 A / TT / A
# 2499-2502 AGTG GTCA TCAC CAGT
# 2642 TCCGAGC deletion of bp AGGCTCG
# 3435 G / C A / T # 3446 G / C A / T # 3643 A / T T / A
In addition, the DNA sequence between the restriction sites AatlI (position # 4364 in pCFM1656) and Sac I I (position # 4585 in pCFM1656) is substituted with the following DNA sequence:
[ext roe sticks j bear of Aat l I]
'CGTAACGTAT - «- ATGGTCTCCCCATGCGAGAGTAGGGAACT < - ?: CAGGCATCAA- 3 'GCACGCATTGCATACGTACCAGAGGGGTAC .- ?: TCTCATCCCTRGACGGTCCGTAGTT- -TAAAACGAAAGGCTCAGTCGAAAGACTCGGCCTTTCG ^ - AT TT CGTTCCGAGTCAGCTTTCGGACCCGGAAAGCAAAATAGACAACAAACAGCCAC - G ^ TAGGCGGCCCRCGCCTAAACTTGCAACGCTTCGTTGCC- -ACGCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGGATTTGAACGTTGCGAAGCAACGG- -TGCGAGAGGACTCATCC -CCGGAGGGTGGCGGGCAGGACGCCCGCCATAAACTGCCAGGCATCAAATTAAGCAGAAG- -GGCCTCCCACCGCCCGTCCTGCGGGCGG ATTTGACGGTCCGTAGT TAATTCGTCTTC- -CCATCCTGACGGATGGCCTTTRRGCGTI CTACAAACTCTTTTGTTRATTTTTCTAAAT- -CGGTAGGACTGCCRACCGGAAAAACGCAAAGATGT??? ^? GAGAAAACAAATAAAAAGATTTA- AatII -ACATTCAAATATGGACGTCTCATAATTTTTAAAAAATTCATTTGACAAATGCTAAAATTC- -TGTAAGTTTATACCTGCAGAGTATTAAAAATrrTTTAAGTAAACTGTTTACGATTTTAAG- -TTGATTAATATTCTCAATTGTGAGCGCTCACAATT ^ ATCGATTTGATTCTAGATTTGAGT- -AACTAATTATAAGAGTTAACACTCGCGAGTGTTAAATAGCTAAACTAAGATCTAAACTCA- -TTTAACTTTTAGAAGGAGGAATAACATATGGTTAACGCGTTGGAATTCGAGCTCACTAGT- -AAATTGAAAATCTTCCTCCTTATTGTATACCAATTGCGCAACCTTAAGCTCGAGTGATCA- SacII -GTCGACCTGCAGGGTACCATGGAAGCTTACTCGAGGATCCGCGGAAAG AAGAAGAAGAAG- - C AGCTGGACGTCCC ATGGTACCTTCGAATG AGCTCCT A - GCGCCTTTCTTCTTCTTCTTC - -AAGAAAGCCCGAAAGGAAGCTGAGTTGGCTGCGGCCACCGCTGAGCAATAACTAGCATAA- - TTCTTTCGGGCTTTCCTTCGACTC AACCG ACGACGGTGGCGACTCGTTATTGATCGT ATT - -CCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTGTTGCTGAAAGGAGGAACCGCTCTT- -GGGGAACCCCSGAGATTTGCCCAGAACTCCCCAAAAAACGACTTTCCTCCTTGGCGAGAA- -CACGCTCTTCACGC 3 '-GTGCGAGAAGTG 5'
[sticky end of SacII] The product of the ligation was transformed into competent host cells of the E strain. col i FM15. The resulting colonies were selected for the production of recombinant protein from those colonies that produce the correct sized protein were verified by the DNA sequence. The correct strain was innoculated for fermentation by transferring a small amount to the Luria Broth (10 g / 1 of Tripticase-Peptone, 10 g / 1 of Yeast Extract, and 5 g / 1 of sodium chloride) and incubation at 30 ° C for sixteen hours with agitation at 250 rpm. The culture was transferred to a sterile medium that had been sterilized in place in a fermenter, then the cell mass was increased using continuous feeds of glucose and organic nitrogen, before being induced with lactose. After induction, the fermentation was stopped, the cells were harvested by centrifugation, the supernatant was removed and the remaining cell paste was frozen.
Purification of proteins. The cells of the paste were broken by homogenization with high pressure and the inclusion bodies were recovered by centrifugation. The inclusion bodies were solubilized in guanidine-HCl, then diluted in urea. After resting for several days, the solution was adjusted to pH 3, diluted with water, centrifuged and eluted in series through columns of cation exchange chromatography and hydrophobic interaction. The peak fractions were combined and sterile filtered.
Isoelectric point and protein loading. The isoelectric points of human NT-3 of the non-cultured type (t-metHuNT-3, SEQ ID NO: 1), and of the analogous products thereof (ie, SEQ ID NO. NOS: 3 and 5) were calculated using the "GCG" protein analysis / DNA sequence Logical Equipment Package available from Genetics Computer Groups, Incs. Madison Wisconsin. The loading of the molecule at a physiological pH (assumed to be pH 7.4) was estimated using the same logic equipment. The pl of the first analogous product T-3 (i-u9, R61A, K64D (SEQ ID NO: 3), was calculated to be approximately 0.9 pH units below that of NT-3 of the non-cultivated type (8.5, compared to 9.4) The loading at a physiological pH (7.4) for this analogous product represented a reduction of approximately 2.5 pH units from that of NT-3 of the non-cultivated type (ie from approximately +7 to + 4.5) The pl for the other analogue, NT-3 (? -7) R61A, K64D (SEQ ID NO: 5) was calculated to be approximately 8.2, which is approximately 1.2 pH units below that the pl of the NT-3 of the non-cultivated type (9.4) In addition, the loading at a physiological pH for this analogous product was decreased by approximately 3.5 pH units, to approximately +3.5, relative to the NT-3 of the type not cultivated (+7).
ELISA assay. The elisa assay was conducted in 96-well plates coated with a monoclonal antibody produced against human NT-3. A polyclonal rabbit antibody conjugated to a horseradish peroxidase was used as the secondary antibody. Serum samples, calibration standards and quality control samples were diluted with the phosphate buffer to a 50% serum matrix before assay.
The sample size was 100 microliters (μl) per well. Each sample was analyzed in duplicate. The limits of quantification were 0.65, 4.00 and 4.05 ng / ml of serum per NT-3 of the non-cultivated type,
NT-3 (i-n9) R61A, K64D and NT-3a-? I7. R61A, K64D, respectively.
Size Exclusion Chromatography (SEC-HPLC). Size exclusion chromatography in each sample was performed using a Waters 600 system in conjunction with a G2000SWXL column (TosoHaas). The samples were eluted at a flow rate of 0.7 ml per minute (ml / min.) In a buffer consisting of 100 mM sodium phosphate, 0.5 M NaCl, pH 6.09. The peaks were detected at a wavelength of 230 nanometers (nm).
Chromatography of Cationic Exchange (CEX-HPLC). The CEX-HPLC was performed using a Waters 625 system with a Resource? Column. (Pharmacia, Uppsala, Switzerland). The samples were eluted at a flow rate of one milliliter per minute using a 0-1 M sodium chloride gradient in 20 mM Tris HCl, pH 8.5. The peaks were detected using a wavelength of 220 nm.
SDS-PAGE Silver Tinted. The proteins were diluted with 2% SDS, mixed with sample buffer, and heated for five minutes in boiling water. The separation was conducted according to the manufacturer's instructions using pre-molded TRIS-Tricine gradient gels, 10-20%, from ISS (Integrated Separations Systems, Natick, MA). The dyeing with silver was done according to the procedure of Blum et al. In Electrophoresis, Volume 8, pages 93-99 (1987).
Mytogenic Bioassay with 3T3trkC Cells. The biological activity of r-metHuNT-3 as a reference standard is determined by means of a mitogenic bioassay of cells using 3T3trkC cells. These cells were created by transferring 3T3 cells (ATCC), which normally does not express the trkC receptor on their surface, with the plasmid pcDNAl / neo (Invitrogen, San Diego, CA) modified to contain the DNA sequence for the receptor protein of human trkC. See Shelton et al., Journal of Neuroscience, Volume 15, page 477-491 (1995) for the sequence of the trkC gene, and Valenzuela et al., Neuron, Volume 10 pages 963-974 (1993) for an illustrative transfection procedure. The transfected cells are maintained at 37 ± 2 ° C, in a high humidity incubator under an atmosphere containing 5.5 ± 1.0% C02 and in a Minimum Essential Medium of Dulbecco with fetal bovine serum and Sulfate G-418. The cells were distributed in 96-well plates for each assay. After approximately twenty-four hours incubation time under the same conditions, the maintenance medium was replaced with RPMI 1640 and the samples cultured, NT-3 (? -? 19) R61A, K64D or NT-3U-U7) R61A, K64D in a dose of 1 milligram per kilogram of body weight (mg / kg) each. The test material was administered either (1) intravenously (IV) as a first dose, then subcutaneously (SC) twenty-four hours after the first dose, or (2) in the reverse manner. Serial blood samples were collected before dosing and at 1, 5, 15 and 30 minutes, and 1, 2, 4 and 8 hours after an IV dose. After subcutaneous dosing, samples were collected at 10 and 30 minutes and at 1, 2, 4, and 8 hours. Blood serum concentrations of NT-3 were determined using an ELISA assay (see above). The antibodies used in the assays were specific for the quantification of NT-3 of the cultured type. Although not fully optimized antibodies exhibited sufficient cross-reactivity with NT-3 (? -u9) R61A, K64D and NT-3 (? -u7) R61A, K64D to allow quantification of these analogous products as well. The standard curves were prepared for protein face (see Figure 4).Test Results:
Characterization of the NT-3 analog products. It was observed that both analogs, NT-3 (? - u9) R61A, K64D and NT-3 (? -? I7) R61A, K64D, retain the activity of NT-3 of the non-cultured type (r-metHuNT-3) in the PC-12 in vitro bioassay (Table 1). In fact, the bioactivity of the analogous products as evaluated in this assay appeared to be somewhat greater than that of the NT-3 of the non-cultured type, indicating perhaps an increased affinity for the trkC receptor (NT-3).
Table 1. In Vitro Bioactivity of NT-3 Proteins Concentration Concentration Percentage of Product Exposed Measure NT-3 (mg / ml) analogous activity (mg / ml) expected (%)
NT-3 of type no 0.32 0.23 72 cultivated NT-3 (i.n7) 0.36 1.18 328
R61A.K64D NT-3 (i - ?? 9) 0.25 1.31 524
R61A.K64D
Both analogous products were eluted as non-covalent dimers in size exclusion HPLC, as well as for NT-3 of the non-cultured type (see Figure 5). As expected, there was no significant difference in the molecular weights of the three proteins. Significant protein aggregation was not detected for any analogue. The results of the cation exchange HPLC (see Figure 6) were consistent with a reduction in pl for both analogs. The change in protein loading probably explains the slight changes in the SDS-PAGE
(Figure 7), compared to NT-3 of the non-cultivated type. Both of the analogous products retain the biological activity and the non-covalent dimer structure of the
NT-3 of the non-cultivated type.
Pharmacokinetic behavior. The concentration curves in the serum after intravenous administration were observed to be biphasic (see Figure
8). There was a significant difference in the initial distribution phase between the different types of NT-3.
The lifetimes (aT? / 2) were 3.3, 5.4 and 7.6 minutes for NT-3 of the non-cultivated type,
NT-3 (? -? I9) R61A, K64D and NT-3 < ? - ?? 7) R61A, K64D, respectively
(see Table 2, later). The decrease observed in the elimination after intravenous administration could be due only to the slower distribution of the analogous NT-3 products. The most pronounced decrease in concentration during this phase was observed with NT-3 of the non-cultivated type. The lifetimes of the terminal phase (ßT? / 2) were similar for the three types and ranged from 0.9 to 1.0 hours, suggesting that the elimination mechanism for these types could be the same. The areas under the concentration-time curves (t-AUCinf) for the NT-3 (? - u9) R61A, K64D and NT-3,? -. 117) R61A, K64D were approximately 1.2 to 2 times that of the NT -3 of the non-cultivated type.
Table 2. Pharmacokinetic Parameters Obtained in Rats with a Given Single IV Dosage of 1 mg / kg of NT-3 Proteins
1 Area under the concentration curve in the serum time from time zero to infinity. The calculation of the area is through the trapezoidal method. 2 The elimination speed is calculated by: Dose + AUC. 3 Period of life of the distribution phase (aT? 2). 4 Period of life of the terminal phase (ßT? / 2).
After subcutaneous injection the concentration in the serum increased rapidly for NT-3 of the non-cultured type (see Figure 9). The time for the maximum concentration (TMAX) was approximately 0.17 hours (see Table 3, below). A slower absorption profile was observed for the specifically modified types, TMAX 'S for NT-3 (i-u9) R61A, K64D and NT-3 (? - u7) R61A, K64D were 0.67 and 1.33 hours, respectively . The maximum concentrations for NT-3 (? -? I9) R61A, K64D and NT-3 (1-? 17) R61A, K64D were 6 to 10 times higher than for NT-3 of the non-cultivated type, which suggests that the analogous products manifested a higher degree of absorption of the injection site after administration. In addition, the degree of absorption (bioavailability) is more typically determined from the ratio of the areas under the serum curves for the routes of subcutaneous and intravenous administration, Table 3. Bioavailability for NT-3 of the non-cultured type, NT-3 (? -? i9) R61A, K64D and NT-3 (1-u7) R61A, K64D were 2.2, 28.5 and 43.22%, respectively. Terminal life times for analogous products appear to be longer than those of the non-cultivated type.
Table 3. Pharmacokinetic Parameters Obtained in Rats with an Individual SC Dose of 1 mg / kg of NT-3 Proteins
1 Area under the curve of concentration in the serum time from time zero to infinity. The calculation of the area is through the trapezoidal method.
2 The bioavailability (F) is calculated by: (t-AUCsc + t-AUCiv) x 100%, where both areas were obtained from the same animal. 3 CMAX is the maximum concentration. 4 TMAX is the time for maximum concentation. 5 Period of life of the terminal phase (ßT? / 2)
The results of these studies show that by increasing the pl of NT-3, one can decrease the rate of elimination after intravenous administration, at least initially, and can also increase the degree of absorption after subcutaneous administration. These results also show that the loading of the protein plays a significant role in the determination of pharmacokinetic behavior. In the case of a basic protein such as NT-3, as well as other cationic proteins, the decrease in the isoelectric point (or the charge at a physiological pH) can lead to a significant improvement in the absorption and bioavailability of the molecule after of subcutaneous administration. From this knowledge, and the description provided herein, it is possible to design new molecules of improved therapeutic value.
It should be noted that the analogous products illustrated in the above description are proposed to be exemplary only, and that additional analogue products of NT-3, as well as other proteins, can be created in view of the present disclosure to achieve points. lower isoelectric cells with longer circulation times and / or higher absorption. In a variation, for example, the analogous proteins, particular to the IDs. FROM THE SEC. NOS: 3 and 5 can be produced by expressing them in a mammalian cell or by secretion in a bacterial strain such that a product "without met" is obtained (ie, the methionine residue in the N-terminus is removed, to give as a result, the polypeptides of SEQ ID NOS: 6 and 7, respectively, as will also be true in the case of the BDNF analog products described below.
BDNF analog products Using the procedures described above for NT-3, the following BDNF analog products were prepared and purified from E. coli and the isoelectric point (pl) and the charge at a physiological pH for BDNF "of the non-cultivated type" (ie, a naturally occurring sequence; see U.S. Patent No. 5,180,820, Figure 5) (ID.
THE SEC. NO: 8) are also displayed for comparison purposes. The positions for substitution are numbered starting with the first residue after the methionine in the mature form of the protein as expressed in E. col i. (That is, the initial methionine residue is not counted).
BDNF, K65D, K73D, K95A, R97A The substitutions were lysine for aspartic acid. at positions 65 and 73, lysine for methionine at position 95 and arginine for alanine at position 97. (SEQ ID NO: 9). pl calculated: 8.46 charge: +4.0
BDNF, P60E, K65D, K73D, K95A Substitutions were proline for glutamic acid at position 60, lysine for arpartic acid at positions 65 and 73 and lysine for alanine at position 95. (SEQ ID NO: 10) ). pl calculated: 8.45 charge: +4.0 BDNF of the uncultivated type pl calculated: 10.23 charge: +9.5
Results of the Biological Test and Characterization 1) In Vitro Bioactivity: Myxogenic Bioassay with PC12 / trkC Cells. In this assay, the biological activity of BDNF of the non-cultured type and the BDNF analog products are determined quantitatively by measuring the incorporation of (MTS) into PC-12 cells (ATCC) that have been transformed to express the trkB receptor ( the high affinity receptor for BDNF). The transformed cells were maintained at 37 ± 2 ° C, in a high humidity incubator under an atmosphere containing 7.5 ± 1% carbon dioxide, in a Dulbecco Minimum Essential Medium containing bovine serum and equine fetal serum and 1% L-glutamine. The cells were distributed in well plates for the assay, and incubation was continued. After approximately forty-eight hours, the maintenance medium was replaced with RPMI 1640 Medium, the test samples were added and the incubation was continued under the same conditions for another 48 hours. The cells were then stained with MTS, incubated under the same conditions for another five hours, and the optical density for each well was read with a microplate reader at 490 nm. The results for the bioactivity of the two BDNF analog products against BDNF of the non-cultured type are given in Table 4, below.
Table 4. In Vitro Bioactivity of BDNF Proteins
2) In vivo Biological Analysis and Results. The biological properties of the analogous products were evaluated in vivo in male Sprague-Dawley rats at a dose of 3.0 milligrams per kilogram of body weight for BDNF, K65D, K73D, K95A, R97A and 1.7 milligrams per kilogram body weight for the BDNF, P60E, K65D, K73D, K95A. The test materials were administered intravenously and subcutaneously, followed by collection of blood samples and measurement of blood serum concentrations (see the same procedure described above) for NT-3 and analogous NT-3 products. ). The pharmacokinetic behavior is given below with respect to each form of administration.
Table 5. Pharmacokinetic Properties in Rats, Intravenous (IV) Individual Dose of BDNF Proteins
Table 6. Pharmacokinetic Properties in Rats, Individual Subcutaneous (SC) Dose of BDNF Proteins
These results show that the introduction of mutations in BDNF of the non-cultured type has a measurable effect on the pharmacokinetic properties. In particular, greater bioavailability is achieved in vi ve for the two analogous BDNF products compared to BDNF of the non-cultured type as reflected by the increased values for t-UAC (inf) after intravenous administration and the increase in t-AUC (inf) and F% after subcutaneous administration. The invention is defined in the appended claims (ix) DESCRIPTION OF THE SEQUENCE: I D. FROM THE SEC. NO: 1:
Met Tyr Ala Glu His Lys Ser His Arg Gly Glu Tyr Ser Val Cys Asp 1 5 10 15 Ser Glu Ser Leu Trp Val Thr Asp Lys Ser Ser Ala He Asp He Arg 20 25 30 Gly His Gln Val Thr Val Leu Gly Glu He Lys Thr Gly Asn Ser Pro
40 45 Val Lys Gln Tyr Phe Tyr Glu Thr Arg Cys Lys Glu Ala Arg Pro Val 50 55 60 Lys Asn Gly Cys Arg Gly He Asp Asp Lys His Trp Asn Ser Gln Cys 65 70 75 80
Lys Thr Ser Gln Thr Tyr Val Arg Ala Leu Thr Ser Glu Asn Asn Lys 85 90 95 Leu Cal Gly Trp Arg Trp He Arg He Asp Thr Ser Cys Val Cys Wing 100 105 110 Leu Ser Arg Lys He Gly Arg Thr 115 120
INFORMATION FOR THE ID. FROM THE SEC. NO: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 360 base pairs (B) TYPE: nucleic acid (C) HEBRA: individual (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE. CDNA
(xi) DESCRIPTION OF THE SEQUENCE: ID. FROM THE SEC, NO: 2 ATGTACGCTG AACACAAATC TCACCGTGGT GAATACTCTG TTTGCGACTC TGAATCTCTG 60
TGGGTTACCG ACAAATCTTC TGCTATCGAC ATCCGTGGTC ACCAGGTTAC CGTTCTGGGT 120 GAAATCAAAA CCGGTAACTC TCCGGTTAAA CAGTACTTCT ACGAAACCCG TTGCAAAGAA 180 GCTGCACCGG TTGACAACGG TTGCCGTGGT ATCGACGACA AACACTGGAA CTCTCAGTGC 240 AAAACCTCTC AGACCTACGT TCGTGCTCTG ACCTCTGAAA ACAACAAGCT TGTTGGTTGG 300 CGTTGGATTC GTATCGACAC CTCTTGCGTT TGCGCTCTGT CTCGTAAAAT CGGTCGTACC 360
(2) INFORMATION FOR THE ID. FROM THE SEC. NO: 3 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 120 amino acids (B) TYPE: amino acid (C) HEBRA: individual (D) TOPOLOGY: unknown (ii) TYPE OF MOLECULE: protein
(xi) DESCRIPTION OF THE SEQUENCE: ID. FROM THE SEC. NO: 3:
Met Tyr Ala Glu His Lys Ser His Arg Gly Glu Tyr Ser Val Cys Asp
1 5 10 15 Ser Glu Ser Leu Trp Val Thr Asp Lys Be Ser Wing Asp He Arg 20 25 30 Gly His Gln Val Thr Val Leu Gly Glu He Lys Thr Gly Asn Ser Pro 35 40 45 Val Lys Gln Tyr Phe Tyr Glu Thr Arg Cys Lys Glu Wing Wing Pro Val 50 55 60 Asp Asn Gly Cys Arg Gly He Asp Asp Lys His Trp Asn Ser Gln Cys 65 70 75 80
Lys Thr Ser Gln Thr Tyr Val Arg Ala Leu Thr Ser Glu Asn Asn Lys 85 90 95 Leu Val Gly Trp Arg Trp He Arg He Asp Thr Ser Cys Val Cys Wing 100 105 110 Leu Ser Arg Lys He Gly Arg Thr 115 120 2) INFORMATION FOR THE ID. FROM THE SEC. NO: 4 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 354 base pairs (B) TYPE: nucleic acid (C) HEBRA: individual (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE. CDNA
(xi) DESCRIPTION OF THE SEQUENCE: ID. FROM THE SEC. NO: 4:
ATGTACGCTG AACACAAATC TCACCGTGGT GAATACTCTG TTTGCGACTC TGAATCTCTG 60 TGGGTTACCG ACAAATCTTC TGCTATCGAC ATCCGTGGTC ACCAGGTTAC CGTTCTGGGT 120 GAAATCAAAA CCGGTAACTC TCCGGTTAAA CAGTACTTCT ACGAAACCCG TTGCAAAGAA 180 GCTGCACCGG TTGACAACGG TTGCCGTGGT ATCGACGACA AACACTGGAA CTCTCAGTGC 240 AAAACCTCTC AGACCTACGT TCGTGCTCTG ACCTCTGAAA ACAACAAGCT TGTTGGTTGG 300 CGTTGGATTC GTATCGACAC CTCTTGCGTT TGCGCTCTGT CTCGTAAAAT CGGT 354
INFORMATION FOR THE ID. FROM THE SEC. NO: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 118 amino acids (B) TYPE: amino acid (C) HEBRA: individual (D) TOPOLOGY: unknown (ii) TYPE OF MOLECULE, protein
(xi) DESCRIPTION OF THE SEQUENCE: ID. FROM SEC NO: 5:
Met Ala Glu His Lys Ser His Arg Gly Glu Ser Val Cys Asp 1 5 10 15
Ser Glu Be Leu Trp Val Thr Asp Lys Ser Be Wing He Asp He Arg 20 25 30 Gly His Gln Val Thr Val Leu Gly Glu He Lys Thr Gly Asn Ser Pro 35 40 45 Val Lys Gln Phe Glu Thr Arg Cys Lys Glu Wing Arg Pro Val 50 55 60 Lys Asn Gly Cys Arg Gly He Asp Asp Lys His Trp Asn Ser Gln Cys 65 70 75 80
Lys Thr Ser Gln Thr Val Arg Ala Leu Thr Ser Glu Asn Asn Lys 85 90 95
Leu Val Gly Trp Arg Trp He Arg He Asp Thr Ser Cys Val Cys Wing 100 105 110 Leu Ser Arg Lys He Gly 115
NFORMATION FOR THE ID. FROM THE SEC. NO: 6 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 119 amino acids (B) TYPE: amino acid (C) HEBRA: individual (D) TOPOLOGY: unknown ii) TYPE OF MOLECULE, protein
(xi) DESCRIPTION OF THE SEQUENCE: ID. FROM THE SEC. NO: 6: Ala Glu His Lys Ser His Arg Gly Glu Ser Val Cys Asp Ser 1 5 10 15 Glu Ser Leu Trp Val Thr Asp Lys Ser Ser Ala He Asp He Arg Gly
25 30 His Gln Val Thr Val Leu Gly Glu He Lys Thr Gly Asn Ser Pro Val 35 40 45 Lys Gln Phe Glu Thr Arg Cys Lys Glu Ala Ala Pro Val Asp 50 55 60 Asn Gly Cys Arg Gly He Asp Asp Lys His Trp Asn Ser Gln Cys Lys 65 70 75 80
Thr Ser Gln Thr Val Arg Ala Leu Thr Ser Glu Asn Asn Lys Leu 85 90 95 Val Gly Trp Arg Trp He Arg He Asp Thr Ser Cys Val Cys Ala Leu 100 105 110 Ser Arg Lys He Gly Arg Thr 115 (2) INFORMATION FOR THE ID. FROM THE SEC. NO: 7 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 117 amino acids (B) TYPE: amino acid (C) HEBRA: individual (D) TOPOLOGY: unknown (ii) TYPE OF MOLECULE, protein
x i) DESC R I PC OF THE S ECUENC IA: I D. FROM THE S EC NO: 7: Ala Glu His Lys Ser His Arg Gly Glu Ser Val Cys Asp Ser
1 5 10 15 Glu Ser Leu Trp Val Thr Asp Lys Ser Be Ala He Asp He Arg Gly 20 25 30 His Gln Val Thr Val Leu Gly Glu He Lys Thr Gly Asn Ser Pro Val 35 40 45 Lys Gln Phe Glu Thr Arg Cys Lys Glu Ala Arg Pro Val Asp 50 55 60 Asn Gly Cys Arg Gly He Asp Asp Lys His Trp Asn Ser Gln Cys Lys 65 70 75 80
Thr Ser Gln Thr Val Arg Ala Leu Thr Ser Glu Asn Asn Lys Leu Val Gly Trp Arg Trp He Arg He Asp Thr Ser Cys Val Cys Ala Leu 100 105 110 Ser Arg Lys He Gly 115
It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.
Having described the invention as above, the content of the following claims is claimed as property.
Claims (48)
1. A polypeptide analog product of a cationic polypeptide, characterized in that the analog product has an amino acid sequence that differs from the native sequence of the original polypeptide by one or more amino acid residues or by chemical modification of one or more amino acid residues in the native sequence, such that the isoelectric point is lower and the life of circulation and / or absorption in vi are increased for the analogous product relative to those same properties in the cationic polypeptide, unmodified.
2. A polypeptide according to claim 1, also characterized by a lower charge under physiological conditions compared to the cationic polypeptide, unmodified.
3. A polypeptide according to claim 1, characterized in that it is an analogous product of a cationic protein selected from the group consisting of neurotrophic factor-3 (NT-3), brain-derived neurotrophic factor (BDNF), growth factor and differentiation of macrophages and keratinocyte growth factor (KGF).
4. A polypeptide according to claim 3, characterized in that it is an analogous product of NT-3.
5. A polypeptide according to claim 4, characterized in that it has the amino acid sequence of the ID. FROM THE SEC. NO: 3
6. A polypeptide according to claim 4, characterized in that it has the amino acid sequence of the ID. FROM THE SEC. NO: 5
7. A polypeptide according to claim 4, characterized in that it has the amino acid sequence of the ID. FROM THE SEC. NO 6
8. A polypeptide according to claim 4, characterized in that it has the amino acid sequence of the ID. FROM THE SEC. NO: 7
9. A polypeptide according to claim 3, characterized in that it is an analogous product of BDNF.
10. A polypeptide according to claim 9, characterized in that it has the amino acid sequence of the ID. FROM THE SEC. NO: 9
11. A polypeptide according to claim 9, characterized in that it has the amino acid sequence of the ID. FROM THE SEC. NO: 10
12. A DNA molecule that encodes a polypeptide analog product of a cationic polypeptide wherein the analog product has an amino acid sequence that differs from the native sequence of the original polypeptide by one or more amino acid residues, or by a chemical modification of one or more amino acid residues in the native sequence, such that the isoelectric point is lower and the life of circulation and / or absorption m vi is increased for the analogous product relative to those same properties in the cationic polypeptide, unmodified.
13. A DNA molecule according to claim 12, characterized in that it encodes a product analogous to a cationic protein selected from the group consisting of NT-3, BDNF, MGDF and KGF.
14. A DNA molecule according to claim 13, characterized in that it encodes the polypeptide analog product of NT-3.
15. A DNA molecule according to claim 14, characterized in that it encodes the polypeptide of the ID. FROM THE SEC. NO: 3
16. A DNA molecule according to claim 14, characterized in that it encodes the polypeptide of the ID. FROM THE SEC. NO: 5
17. A DNA molecule according to claim 15, characterized in that it has the nucleic acid sequence of the ID. FROM THE SEC. NO: 2
18. A DNA molecule according to claim 16, characterized in that it has the nucleic acid sequence of the ID. FROM THE SEC. NO: 4
19. A DNA molecule according to claim 13, characterized in that it encodes an analogous product of BDNF polypeptide.
20. A DNA molecule according to claim 19, characterized in that it encodes the polypeptide of the ID. FROM THE SEC. NO: 9
21. A DNA molecule according to claim 19, characterized in that it encodes the polypeptide of the ID. FROM THE SEC. NO: 10
22. A biologically functional expression vector characterized in that it includes a DNA molecule according to claim 12 operably linked to the regulatory expression sequences.
23. A prokaryotic or eukaryotic host cell transformed or transfected with an expression vector according to claim 22 in a manner that allows the host cell to express the polypeptide encoded by the DNA molecule.
24. A bacterial host cell, transformed or transfected according to claim 23.
25. A host cell of E. col i, transformed or transfected according to claim 24.
26. A mammalian host cell, transformed or transfected according to claim 23.
27. A CHO cell, transformed or transfected according to claim 26.
28. A COS cell, transformed or transfected according to claim 26.
29. A process for the production of a polypeptide analog product of a cationic polypeptide, wherein the analog product has an amino acid sequence that differs from the native sequence of the original polypeptide by one or more amino acid residues, such that the isoelectric point is lower and the life of circulation and / or absorption in vi is increased for the analogous product relative to those same properties in the unmodified polypeptide, the method is characterized in that it comprises culturing under conditions of suitable nutrients a prokaryotic or eukaryotic host cell transformed or transfected with an expression vector comprising a DNA molecule encoding the polypeptide in a manner that allows the host cell to express the polypeptide, and optionally isolating the polypeptide product from the expression.
30. A method according to claim 29, characterized in that the polypeptide is an analogous product of NT-3.
31. A method according to claim 30, characterized in that the DNA molecule has been prepared by site-directed mutagenesis.
32. A method according to claim 30, characterized in that the analogous product has the amino acid sequence of the ID. FROM THE SEC. NO: 3
33. A method according to claim 30, characterized in that the analogous product has the amino acid sequence of the ID. FROM THE SEC. NO: 5
34. A method according to claim 30, characterized in that the analogous product has the amino acid sequence of the ID. FROM THE SEC. NO 6.
35. A method according to claim 30, characterized in that the analogous product has the amino acid sequence of the ID. FROM THE SEC. NO: 7
36. A method according to claim 29, characterized in that the polypeptide is an analogous product of BDNF.
37. A method according to claim 36, characterized in that the DNA molecule has been prepared by site-directed mutagenesis.
38. A method according to claim 36, characterized in that the analogous product has the amino acid sequence of the ID. FROM THE SEC. NO: 9
39. A method according to claim 36, characterized in that the analogous product has the amino acid sequence of the ID. FROM THE SEC. NO: 10
40. A method according to claim 29, characterized in that the host cell is bacterial.
41. A method according to claim 40, characterized in that the bacterial host cell is E. col i.
42. A polypeptide product of expression in a eukaryotic or prokaryotic host cell of a DNA molecule according to claim 12.
43. An antibody against a polypeptide according to claim 1.
44. An antibody according to claim 43, characterized in that it is polyclonal.
45. An antibody according to claim 43, characterized in that it is monoclonal.
46. A PEG-treated derivative of a polypeptide according to claim 1.
47. A pharmaceutical composition characterized in that it comprises a therapeutically effective amount of a polypeptide according to claim 1 and a pharmaceutically acceptable carrier or diluent.
48. A method for the treatment of peripheral neuropathies, characterized in that it comprises administering to a patient having the disorder a therapeutically effective amount of a polypeptide according to claims 4 or 9.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/684,353 | 1996-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99000372A true MXPA99000372A (en) | 1999-09-20 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6211150B1 (en) | Analogs of cationic proteins | |
CN114671941B (en) | Nerve growth factor mutant | |
EP2238983B1 (en) | Neublastin variants | |
JP2007209349A (en) | Novel neurotrophic factor | |
CA2210644A1 (en) | Ligands for eph-like receptors | |
JPH10507080A (en) | Analogs of epidermal keratinocyte growth factor | |
CN109535243B (en) | Human hepatocyte growth factor mutant and its application | |
US6271364B1 (en) | Analogs of NT-3 | |
MXPA99000372A (en) | Products analogues of proteins cationi | |
AU654142B2 (en) | Stable and bioactive modified somatotropins | |
DE69032471T2 (en) | PROTEINS WITH ONCOSTATIN-M ACTIVITY AND METHOD FOR THE PRODUCTION THEREOF | |
CA2097878C (en) | Therapeutic agent for neutropenia | |
CN100334114C (en) | Novel fusion protein production and uses | |
JP2001523113A (en) | Sodium channel receptor | |
CA2120693A1 (en) | Polypeptide and dnas encoding it | |
JPH06340697A (en) | New polypeptide, its production, dna capable of coding the same polypeptide, vector composed of the same dna, host cell transformed with the same vector, antibody against the same polypeptide and pharmaceutical composition containing the same polypeptide or antibody |